Thompson Siegel & Walmsley LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 65.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 111,305 shares of the biopharmaceutical company's stock after buying an additional 43,921 shares during the quarter. Thompson Siegel & Walmsley LLC's holdings in Gilead Sciences were worth $9,332,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. boosted its position in shares of Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 238 shares during the period. nVerses Capital LLC bought a new stake in shares of Gilead Sciences in the third quarter worth $25,000. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Cedar Wealth Management LLC grew its holdings in Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Price Performance
NASDAQ:GILD traded up $0.32 during mid-day trading on Friday, reaching $90.08. 666,142 shares of the stock were exchanged, compared to its average volume of 7,063,990. The firm has a market capitalization of $112.26 billion, a PE ratio of 998.22, a PEG ratio of 2.72 and a beta of 0.17. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The business has a fifty day moving average price of $87.28 and a 200 day moving average price of $76.61. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 earnings per share. Research analysts expect that Gilead Sciences, Inc. will post 4.38 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.42%. Gilead Sciences's payout ratio is presently 3,422.22%.
Wall Street Analyst Weigh In
Several research analysts have recently commented on GILD shares. Oppenheimer lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Barclays lifted their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a report on Thursday, November 7th. Wolfe Research started coverage on shares of Gilead Sciences in a report on Friday, November 15th. They set an "outperform" rating and a $110.00 target price on the stock. BMO Capital Markets lifted their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Finally, Citigroup started coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 price target on the stock. Twelve analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $95.41.
Get Our Latest Stock Analysis on Gilead Sciences
Insider Buying and Selling
In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company's stock, valued at $8,398,843.87. This represents a 1.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,947 shares of company stock valued at $4,968,674. Insiders own 0.16% of the company's stock.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
